| Name | Title | Contact Details |
|---|
Coherent Logix is a Austin, TX-based company in the Computers and Electronics sector.
Nova Measuring Instruments Ltd. is a leading provider of advanced, high-throughput metrology solutions for semiconductor manufacturing worldwide. Used by over 80% of the largest integrated-circuit manufacturers, Nova’s solutions deliver the high-volume complex measurements required for effective process control. Nova offers a selection of Integrated and Stand-Alone metrology platforms, which are complimented by the powerful NovaMARS® modeling engine. This flexible offering enables Nova to partner with semiconductor manufacturers throughout the entire product lifecycle; from application development to high-volume production. Featuring a unique combination of Spectroscopic Reflectrometry and Scatterometry, Nova’s metrology solutions measure a wide variety of features and parameters including CD, trench depth, photoresist height, thickness and shape of complex layer stacks. With Nova, you get the tight wafer-to-wafer and within-wafer control necessary to develop and produce advanced 2D/3D structures for high-end semiconductor devices. Founded in 1993, Nova’s headquarters are located in Israel and the company has offices in Taiwan, Korea, Singapore, China, United States, Japan and Europe.
Materials and Technologies Corp is a Poughkeepsie, NY-based company in the Computers and Electronics sector.
Market Magic Direct Mail is a Leavenworth, WA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.